Summary
Combination chemo-immunotherapy is a primary treatment option for patients with advanced non-small cell lung cancer (NSCLC). Although PD-L1 is a biomarker for selecting patients for therapy, it is imperfect, and the benefit of adding chemotherapy varies among patients. To address this, Cellworks developed a mechanistic computational biology model that integrates a patient’s tumor-specific genomic profile, identified through comprehensive genomic profiling (CGP). This model reveals signaling pathway dysregulation and predicts variable immune checkpoint inhibitor (ICI) and ICI + chemotherapy (ICI+C) responsiveness. The model's output is translated into a quantitative score called the delta Therapy Response Index (ΔTRI), which represents the likelihood of chemotherapy benefit regardless of PD-L1 status.